• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

已治愈的肝细胞癌 (HCC) 对非干扰素治疗根除丙型肝炎感染后新发生 HCC 的影响。

Impact of previously cured hepatocellular carcinoma (HCC) on new development of HCC after eradication of hepatitis C infection with non-interferon-based treatments.

机构信息

Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan.

Department of Radiology, Ogaki Municipal Hospital, Ogaki, Japan.

出版信息

Aliment Pharmacol Ther. 2018 Sep;48(6):664-670. doi: 10.1111/apt.14914. Epub 2018 Jul 25.

DOI:10.1111/apt.14914
PMID:30047149
Abstract

BACKGROUND

The incidence of hepatocellular carcinoma (HCC) in patients with a history of curatively-treated HCC is higher than in patients with no history of HCC even after sustained virologic response (SVR).

AIM

To investigate differences in the patterns of HCC development after SVR in patients with a history of curatively-treated HCC and those with no history of HCC, based on gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging (EOB-MRI) findings.

METHODS

EOB-MRI was performed in 164 patients with HCV cirrhosis who achieved SVR by interferon-free direct-acting antiviral (DAA) therapy just before the start of therapy. Changes in EOB-MRI findings after SVR were compared prospectively between patients with (n = 62) and without (n = 102) a history of HCC.

RESULTS

The incidence of HCC after SVR was higher in patients with a history of HCC (P < 0.0001). The prevalence of nonhypervascular hypointense nodules (NHHNs) by EOB-MRI was significantly higher in patients with a history of HCC at baseline (P = 0.05). Although there was no difference in the incidence of the hypervascularisation of baseline NHHNs to typical hypervascular HCC between patients with and without a history of HCC, the incidence of direct emergence of hypervascular HCC despite the absence of NHHNs at baseline was significantly higher in patients with a history of HCC (P < 0.0001).

CONCLUSION

Direct emergence of hypervascular HCC and a higher prevalence of NHHNs before DD therapy contributed to the higher incidence of HCC after SVR. (UMIN000017020).

摘要

背景

即使在获得持续病毒学应答(SVR)后,有根治性 HCC 治疗史的患者的 HCC 发病率仍高于无 HCC 病史的患者。

目的

基于钆塞酸二钠增强磁共振成像(EOB-MRI)结果,探讨有和无 HCC 治疗史的患者在获得 SVR 后 HCC 发展模式的差异。

方法

对 164 例接受无干扰素直接作用抗病毒(DAA)治疗的 HCV 肝硬化患者进行 EOB-MRI 检查,这些患者在治疗开始前均获得 SVR。前瞻性比较有(n=62)和无(n=102) HCC 治疗史的患者在 SVR 后 EOB-MRI 检查结果的变化。

结果

SVR 后 HCC 的发生率在有 HCC 治疗史的患者中更高(P<0.0001)。基线时 EOB-MRI 存在非血供低信号结节(NHHN)的患者比例在有 HCC 治疗史的患者中明显更高(P=0.05)。虽然有和无 HCC 治疗史的患者基线 NHHN 向典型血供型 HCC 高血供化的发生率没有差异,但有 HCC 治疗史的患者基线时无 NHHN 而直接出现血供型 HCC 的发生率明显更高(P<0.0001)。

结论

DD 治疗前直接出现血供型 HCC 和 NHHN 发生率较高导致 SVR 后 HCC 发病率升高。(UMIN000017020)。

相似文献

1
Impact of previously cured hepatocellular carcinoma (HCC) on new development of HCC after eradication of hepatitis C infection with non-interferon-based treatments.已治愈的肝细胞癌 (HCC) 对非干扰素治疗根除丙型肝炎感染后新发生 HCC 的影响。
Aliment Pharmacol Ther. 2018 Sep;48(6):664-670. doi: 10.1111/apt.14914. Epub 2018 Jul 25.
2
The impact of HCV eradication by direct-acting antivirals on the transition of precancerous hepatic nodules to HCC: A prospective observational study.直接作用抗病毒药物清除 HCV 对癌前肝结节向 HCC 转化的影响:一项前瞻性观察研究。
Liver Int. 2019 Mar;39(3):448-454. doi: 10.1111/liv.13987. Epub 2018 Nov 2.
3
Pretreatment non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI as a predictor of hepatocellular carcinoma development after sustained virologic response in HCV infection.钆塞酸二钠增强 MRI 上治疗前非富血供低信号结节作为 HCV 感染持续病毒学应答后肝细胞癌发展的预测因子。
Aliment Pharmacol Ther. 2021 Jun;53(12):1309-1316. doi: 10.1111/apt.16382. Epub 2021 Apr 25.
4
Identification of the suitable candidates for EOB-MRI with the high risk of the presence of non-hypervascular hypointense nodules in patients with HCV infection.识别 HCV 感染患者中存在非富血供低信号结节高风险的 EOB-MRI 合适人选。
Eur Radiol. 2022 Jul;32(7):5016-5023. doi: 10.1007/s00330-022-08570-4. Epub 2022 Feb 10.
5
Hepatocellular carcinoma incidence post direct-acting antivirals in hepatitis C-related advanced fibrosis/cirrhosis patients in Australia.澳大利亚丙型肝炎相关晚期纤维化/肝硬化患者使用直接抗病毒药物后的肝细胞癌发病率
Hepatobiliary Pancreat Dis Int. 2020 Dec;19(6):541-546. doi: 10.1016/j.hbpd.2020.06.013. Epub 2020 Jun 30.
6
Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores.在基线肝硬化或高 FIB-4 评分的患者中,HCV 清除后长达 10 年仍存在肝细胞癌风险增加。
Gastroenterology. 2019 Nov;157(5):1264-1278.e4. doi: 10.1053/j.gastro.2019.07.033. Epub 2019 Jul 26.
7
Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents.直接作用抗病毒药物治疗的 HCV 患者的肝细胞癌风险。
Gastroenterology. 2017 Oct;153(4):996-1005.e1. doi: 10.1053/j.gastro.2017.06.012. Epub 2017 Jun 19.
8
Impact of the introduction of direct-acting anti-viral drugs on hepatocarcinogenesis: a prospective serial follow-up MRI study.直接作用抗病毒药物的引入对肝癌发生的影响:一项前瞻性系列随访 MRI 研究。
Aliment Pharmacol Ther. 2020 Jul;52(2):359-370. doi: 10.1111/apt.15825. Epub 2020 Jun 10.
9
Systematic review with meta-analysis: effectiveness of direct-acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma.系统评价与荟萃分析:直接作用抗病毒治疗对合并肝细胞癌的丙型肝炎患者的疗效。
Aliment Pharmacol Ther. 2020 Jan;51(1):34-52. doi: 10.1111/apt.15598. Epub 2019 Dec 6.
10
Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals.直接作用抗病毒药物治疗的丙型肝炎肝硬化患者发生肝细胞癌的预测因素。
Dig Liver Dis. 2019 Feb;51(2):310-317. doi: 10.1016/j.dld.2018.10.014. Epub 2018 Oct 31.

引用本文的文献

1
Simple new clinical score to predict hepatocellular carcinoma after sustained viral response with direct-acting antivirals.一种简单的新型临床评分,用于预测直接作用抗病毒药物治疗后获得持续病毒学应答的患者发生肝细胞癌。
Sci Rep. 2023 Jun 2;13(1):8992. doi: 10.1038/s41598-023-36052-0.
2
Management and Treatment of Hepatocellular Carcinoma with Immunotherapy: A Review of Current and Future Options.免疫疗法治疗肝细胞癌:当前与未来选择的综述
J Clin Transl Hepatol. 2020 Jun 28;8(2):168-176. doi: 10.14218/JCTH.2020.00001. Epub 2020 Jun 10.
3
Hypovascular tumors developed into hepatocellular carcinoma at a high rate despite the elimination of hepatitis C virus by direct-acting antivirals.
尽管直接作用抗病毒药物消除了丙型肝炎病毒,但低血供肿瘤仍有较高的发展为肝细胞癌的风险。
PLoS One. 2020 Aug 13;15(8):e0237475. doi: 10.1371/journal.pone.0237475. eCollection 2020.
4
Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein but not α-fetoprotein as a Long-Term Hepatocellular Carcinoma Predictor.槐凝集素阳性 Mac-2 结合蛋白而非甲胎蛋白作为长期肝细胞癌预测指标。
Int J Mol Sci. 2020 May 21;21(10):3640. doi: 10.3390/ijms21103640.
5
APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation.APASL HCV 指南:DAA 治愈的 HCV 患者应如何监测 HCC 发生和 HBV 再激活。
Hepatol Int. 2019 Nov;13(6):649-661. doi: 10.1007/s12072-019-09988-7. Epub 2019 Sep 20.
6
TINAGL1 promotes hepatocellular carcinogenesis through the activation of TGF-β signaling-medicated VEGF expression.TINAGL1通过激活转化生长因子-β信号介导的血管内皮生长因子表达促进肝细胞癌发生。
Cancer Manag Res. 2019 Jan 15;11:767-775. doi: 10.2147/CMAR.S190390. eCollection 2019.